Company: 

Nabriva Therapeutics

Nabriva Therapeutics

The Niche medical writing team was involved in drafting clinical study protocols, providing a succinct but bespoke service to help support efforts in progressing an early-phase clinical program, with a tailored focus on the United States Food and Drug Administration. Niche medical writers also provided writing and editorial services for the creation and publishing of a clinical research manuscript.

The services required were targeted at providing comprehensive clinical study protocols and a manuscript with quick turnaround times to provide a solid framework to kickstart progress on a successful early-phase clinical development pathway. Additional ad hoc work helped bolster the clinical research package.

Following support by the Niche team, Lefamulin the drug for which Niche contributed to the writing of study protocols, saw successful CTA results and has since progressed through the clinical development pathway and was successfully approved by the FDA, EMA and Health Canada. Additionally, the manuscript was published in The Journal of Antimicrobial Chemotherapy.

What our client said

"I continue to use Niche Science and Technology in my present endeavours, where they work seamlessly with my staff to prepare various clinical study documentation and submissions."

photophotophotophotophoto

Dr William T Prince

Nabriva Therapeutics




Project background
Nabriva Therapeutics is a biopharmaceutical company focused on developing and commercialising innovative antibiotics to treat serious infections caused by drug-resistant bacteria. Nabriva was established as a spin-off from the Sandoz GmbH Antibiotics Research Institute in Vienna. Founded in 2006 and headquartered in Dublin, Ireland, the company is particularly known for its lead product, lefamulin, which is a novel antibiotic approved for the treatment of community-acquired bacterial pneumonia. Nabriva aims to address the growing global health crisis of antibiotic resistance by advancing its pipeline of proprietary therapies, having initiated three clinical development programs, ranging eight different indications. With a dedicated team of scientists and healthcare professionals, the company is committed to enhancing patient outcomes and providing effective solutions for challenging infections, while also collaborating with regulatory bodies and healthcare providers to promote responsible antibiotic use.
Delivery

Niche began work with Nabriva in 2010, writing key documents and standard operating procedures for their quality management system. This was followed by providing support in delivering regulatory writing for BC-3205, a novel representative of pleuromutilins, a new class of antibiotics for human use, and BC-3781, a semi-synthetic pleuromutilin. The Niche were involved in wring a series of protocols, CSRs, IMPDs and Investigator Brochure updates. As these assets matured the Niche became involved in writing manuscripts for submissions to scientific journals as well as coordinating the manuscript submissions and responses to reviewers.

Related Case studies

Medical writing

The FRAILOMIC initiative was an international research project

Niche built and coordinated the full communications strategy for this 20-institution European initiative, turning.

read more
Medical writing

Cleothena Enterprises Pty Ltd. is a forward-thinking biotechnology company focused on advancing innovative therapeutic solutions.

When stalled regulatory documentation threatened to derail their neurological programme, Cleothena turned to Niche —.

read more
Medical writing

BSH is the UK’s largest haematology organisation, promoting excellence within the field and supporting professional development.

Over a decade and 20+ guidelines later, Niche remains the BSH's trusted partner for raising haematology care standards.

read more
Medical writing

A specialist pharmaceutical company dedicated to HIV medicines and research with an extensive portfolio of prescription medicines.

Putting patients first, Niche supported ViiV Healthcare's global HIV outreach programmes with medical writing,.

read more
Medical writing

Specialising in the discovery and development of small-molecule drugs for oncology and central nervous system disorders.

Niche provided Astex with expert regulatory writing across their oncology pipeline, delivering clinical protocols, study.

read more
Medical writing

QC review of an IB update for uzatresgene autoleucel, one of Adaptimmune’s TCR-based therapies.

Niche delivered rigorous QC and medical writing support across Adaptimmune's full suite of regulatory documents, keeping.

read more
Medical writing

Partnership with a clinical research organisation specialising in comprehensive data services for clinical trials.

For over a decade, Assign DMB relied on Niche as their embedded writing partner, seamlessly converting statistical.

read more
Medical writing

Providing regulatory and medical writing support to meet client needs

Niche served as the English-language regulatory writing backbone for this Nordic consultancy, producing IBs, IMPDs and.

read more

Get our latest news and publications

Sign up to our news letter

© 2025 Niche.org.uk     All rights reserved

HomePrivacy policy Corporate Social Responsibility